Shareholders of this Cayman blank-check vehicle have already approved the Nanyang Biologics combination, yet the equity still trades as a stub rather than as a closed operating company. The mid-August vote cleared every proposal on the card by a wide margin, which removes the corporate-approval hurdle that had sat over the stock since the October signing. What the vote does not remove is the remaining close conditions, the Nasdaq listing step, and a public float that successive redemption windows have already gutted. The investment debate is no longer whether holders back the deal. It is whether a preclinical Singapore discovery shop with a first year of token commercial sales can support a billion-plus listing once the stub converts one-for-one into the new holding company.
The cash that once sat in trust has already been hollowed out twice. An extension vote last November sent more than $71 million out the door. A second extension window in August sent another $9 million to holders who preferred the floor. Preliminary deal-vote redemption requests then covered nearly four million additional shares, which is almost the entire remaining public book. After those windows, almost nothing of the original float remains to fund Nanyang. The market still prices the leftover stub at several times the trust floor, which means holders who stay are underwriting the target story rather than collecting cash.
Second-quarter results are a shell print: a thin slice of trust interest, a larger administrative load, almost no cash outside the lockbox, and a going-concern paragraph. Nanyang's own fiscal year showed first commercial sales below $85 thousand and a reported profit that rested on a one-time non-cash gain from ending a university collaboration. The question the next several months resolve is simple. Does the combination actually close into a listed NYB, or does the stub keep trading as a thin claim on a deal that still has conditions left?